You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Common OCD drug may be used in early treatment for Covid-19, say scientists

In the study, the 152 trial participants, all of whom were 18 years or older, were diagnosed with mild forms of Covid-19

Topics
Obsessive-Compulsive Disorder (OCD) - Everything You Need To Know | Vaccine | Coronavirus Vaccine

Press Trust of India  |  Boston 

Obsessive Compulsive Disorder, OCD
Photo: Shutterstock

Scientists have found that a drug commonly used to treat obsessive-compulsive disorder, or OCD, if taken within seven days of first symptoms of COVID-19, may reduce the risk for respiratory deterioration, an advance that might lead to a new treatment strategy for the novel coronavirus infection.

The study, published in the journal JAMA, noted that none of the 80 patients who took the antidepressant fluvoxamine met the respiratory deterioration criteria -- compared to an 8.3 per cent rate in the 72 patients who took a dummy pill (placebo).

"The results of the fluvoxamine trial are encouraging and warrant a further evaluation in a larger study. A treatment that can prevent lung problems in people with mild symptoms of COVID-19 is desperately needed," said study co-author Carolyn Machamer from the Johns Hopkins School of Medicine in the US.

According to the scientists, fluvoxamine, which is typically used to treat patients with OCD, has strong anti-inflammatory properties.

They believe this capability could prevent cytokine storms -- the body's massive, sometimes deadly, inflammatory reaction to the coronavirus.

In the study, the 152 trial participants, all of whom were 18 years or older, were diagnosed with mild forms of COVID-19, and randomly assigned to take either fluvoxamine or a placebo.

The scientists said none of the 80 participants who received the drug hit the endpoint of clinical deterioration, as opposed to six of the 72 people in the placebo group whose blood oxygen levels significantly lowered.

Based on the results, the researchers said fluvoxamine has the potential to reduce the risk of hospitalisation in COVID-19 patients.

"We now have evidence that an inexpensive, safe, and readily available pill can reduce deterioration and hospitalisation from COVID-19," said Steve Kirsch, another co-author of the study.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, November 13 2020. 18:05 IST
RECOMMENDED FOR YOU